Long‐term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90‐yttrium‐ibritumomab‐tiuxetan

Abstract

This is one of the largest single institution reports assessing the risk of SPN in FL patients treated (96) or not (146) with 90Y-IT. It seems that 90Y-IT does not increase significantly the risk of SPN but avoiding its use after fludarabine and other intense cytotoxic schemes is recommended.

A retrospective study of R‐DHAP/Ox for early progressing follicular lymphoma

“…Four patients (8·6%) experienced transformation to DLBCL; one acute leukaemia and one myelodysplastic syndrome were also reported. Acute toxicities were consistent with previously reported series of ASCT, while rates of secondary malignancies were comparable to other series with less intensive treatments (McLaughlin et al , ; Xu et al , ; Andrade‐Campos et al , ).…”

FZD10‐targeted α‐radioimmunotherapy with 225Ac‐labeled OTSA101 achieves complete remission in a synovial sarcoma model

“…However, there is a report about the risk of secondary primary malignancy of the radioimmunotherapeutic pharmaceutical 90 Y-labeled Zevalin for non-Hodgkin lymphoma. 36 The follow-up analysis of 242 patients showed no difference in secondary cancer incidence between 90 Y-labeled Zevalin and other therapy. 36 Unfortunately, there is no report of the risk of secondary cancer related to alpha-RIT.…”

“…36 The follow-up analysis of 242 patients showed no difference in secondary cancer incidence between 90 Y-labeled Zevalin and other therapy. 36 Unfortunately, there is no report of the risk of secondary cancer related to alpha-RIT. Further clinical studies are required to assess potential risks.…”

90Y‐ibritumomab‐tiuxetan as a therapeutic alternative for follicular lymphoma (FL): A single‐center experience

“…As an alternative, radioimmunoconjugates on the basis of anti‐CD20 principles (eg 90 Y‐ibritumomab‐tiuxetan) can be applied for patients after chemotherapy as consolidation . The linkage of a particle‐emitting isotope radiotherapy targets tissue with presence of CD‐20‐expressing cells.…”

“…6,16 As an alternative, radioimmunoconjugates on the basis of anti-CD20 principles (eg 90 Y-ibritumomab-tiuxetan) can be applied for patients after chemotherapy as consolidation. [20][21][22] The linkage of a particle-emitting isotope radiotherapy targets tissue with presence of CD-20-expressing cells. In comparison with external beam radiation therapy, targeted antibody therapy can result in a higher local penetration, especially in patients with bulky disease.…”